Concepedia

Liver Toxicity After Switching or Simplifying to Nevirapine-Based Therapy Is Not Related to CD4 Cell Counts: Results of the TOSCANA Study

Antonio Antela, Antonio Ocampo, Rocío Gómez, María Jesús López, Ana Mariño, Elena Losada, Raúl Rodríguez, Ricardo Fernández, Juan Corredoira, Genoveva Naval,

HIV Clinical Trials · 2010 · 16 citations · 13 references

DOI

Abstract

Switching to nevirapine was associated with a low incidence of liver toxicity that was unrelated to high CD4 cell counts in patients on prior antiretroviral therapy undergoing simplification or substitution therapy.

References

13

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

Annals of Internal Medicine · 1998 · 5.2K citations

Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection

David L. Paterson, Susan Swindells, Jeffrey Mohr et al. · Annals of Internal Medicine · 2000 · 3.3K citations

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

Frank van Leth, Praphan Phanuphak, Kiat Ruxrungtham et al. · The Lancet · 2004 · 683 citations

, , +9

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

Estebán Martínez, José Luís Blanco, Juan A. Arnaiz et al. · AIDS · 2001 · 351 citations

Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

Estebán Martínez, Juan A. Arnaiz, Daniel Podzamczer et al. · New England Journal of Medicine · 2003 · 293 citations · Full text